Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(12,13-Desoxyepothilone B; Desoxyepothilone B; KOS 862)
Epothilone D Chemical Structure
|Product name: Epothilone D|
|Cat. No.: HY-15278|
Epothilone D(Desoxyepothilone B; KOS 862) is a natural polyketide compound isolated from the myxobacterium Sorangium cellulosum.
Epothilone D binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis, cellular proliferation, and cell motility. Intermediary obtained in the synthesis of members of the Epothilone family, polyketide natural products that inhibit cancer cells via a mechanism similar to Paclitaxel. Epothilone D also found to be effective against Paclitaxel-resistant tumors. Epothilone D currently in Phase I of clinical testing.
|M.Wt||491.68||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.0338 mL||10.1692 mL||20.3384 mL|
|5 mM||0.4068 mL||2.0338 mL||4.0677 mL|
|10 mM||0.2034 mL||1.0169 mL||2.0338 mL|
. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy By Brunden, Kurt R.; Zhang, Bin; Carroll, Jenna; Yao, Yuemang; Potuzak, Justin S.; Hogan, Anne-Marie L.; Iba, Michiyo; James, Michael J.; X The Journal of Neuroscience, 13 October 2010, 30(41): 13861-13866;
. Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Miranov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, Aghajanian CPhase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Invest New Drugs. 2011 Nov 10.
. Monk JP, Villalona-Calero M, Larkin J, Otterson G, Spriggs DS, Hannah AL, Cropp GF, Johnson RG, Hensley ML. A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin?) in patients with advanced solid tumors. Invest New Drugs. 2012 Aug;30(4):1676-83.
. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Trojanowski JQ. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci. 2010 Oct 13;30(41):13861-6.
10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.
10-Oxo Docetaxel(Docetaxel Impurity) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.
2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 (plusmn) 0.11 (mu)M for the inhibition of BPAEC migration.
4(acute)-Demethylepipodophyllotoxin(4(acute)-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.
7-Epi-10-oxo-docetaxel (Docetaxel Impurity D) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).
7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.
7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.
ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 (mu)M in neuroblastoma and non-neuroblastoma cell lines, respectively.
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.
Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates.